astrazeneca.com.br

AstraZeneca Brasil
One of the world's leading biopharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference ... AstraZeneca - a global research-based biopharmaceutical company
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. Discover the ground-breaking work that we do at AstraZeneca.com AstraZeneca
AstraZeneca - Brazil
Rodovia Raposo Tavare KM 26 Cotia-Sao Paulo 55 11 3737 1200 55 11 4612 2574 http://www.astrazeneca.com.br/ AstraZeneca - Home
AstraZeneca is a major contributor to UK science and innovation investment, economic prosperity and to patient health. Read more about our UK presence AstraZeneca appoints Marta Brito Pérez HR VP, North America and ...
AstraZeneca has announced the appointment of Marta Brito Pérez as Human Resources Vice President, North America and Global Marketing. AstraZeneca - United States Home Page
Learn about AstraZeneca, a global, innovation-driven biopharmaceutical company, and get information on our medicines, patient assistance programs, and more. AstraZeneca - Home
AstraZeneca Australia is engaged in the research, development, manufacture and supply of medicines that aim to make a real difference to the lives of Australians. AstraZeneca Is Undervalued - Seeking Alpha
AstraZeneca (AZN) has had a lackluster stock price performance in recent years. Despite the lackluster stock price performance, AstraZeneca sports a high dividend ... AstraZeneca Websites weltweit - AstraZeneca Deutschland
Eine Übersicht über alle AstraZeneca Websites weltweit ... Diese Seite bietet Links zu einer Anzahl AstraZeneca Websites, so auch Sites über unsere Produkte, die ...

AstraZeneca Will Soar On 2 New Drugs In 2013
Cancer Research UK's Drug Development Office has begun a clinical trial to test AstraZeneca's (AZN) AZD4547 drug. This drug may, if combined with chemotherapy, treat stomach or esophageal cancer. This is the first trial launched by the ECMC Combinations Alliance. AstraZeneca Buys Ardea Biosciences
AstraZeneca plc (AZN) recently announced that it has completed the acquisition of Ardea Biosciences, Inc. for approximately $1.26 billion or $32 per share. Both AstraZeneca and Ardea’s boards unanimously supported the merger. Ardea’s ... UPDATE 1-Novartis, Astra win EU drug okays; Pfizer loses out
LONDON, June 22 (Reuters) - Novartis and AstraZeneca won recommendations for important new drugs from European regulators on Friday, while rival Pfizer lost out. The European Medicines Agency said its Committee for Medicinal Products for Human ... AstraZeneca, RIGL in Licensing Deal
AstraZeneca (AZN) and Rigel Pharmaceuticals, Inc. (RIGL) recently announced that they have entered into a licensing agreement for Rigel’s asthma candidate, R256. Per the terms of the agreement, AstraZeneca will make an upfront payment of $1 ... AstraZeneca Completes Purchase of Ardea Biosciences (AZN)
Jun 20, 2012 (SmarTrend(R) News Watch via COMTEX) -- 6-20-2012- AstraZeneca PLC (NYSE:AZN) announced that it has completed its purchase of Ardea Biosciences Inc. The deal for AstraZeneca to acquire Ardea Biosciences for $1.26 billion was ... AstraZeneca Buys 300,000 Shares to Cancel/2751P
AstraZeneca PLC announced Thursday that it purchased for cancellation 300,000 of its own ordinary shares at a price of 2751 pence per share. -Shares at 0725 GMT up 13 pence, or 0.5%, at 2,780 pence, valuing the company at GBP35.1 billion. AstraZeneca, Rigel enter global license agreement for R256 inhaled JAK inhibitor to treat chronic asthma
AstraZeneca and Rigel Pharmaceuticals Inc. today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signalling, which is ... GlaxoSmithKline and AstraZeneca launch pioneering approach to antibiotic research
It was announced today that GlaxoSmithKline and AstraZeneca have launched a pioneering approach to antibiotic research in Europe to attempt to tackle the rising threat from antibiotic resistance and address some of the key barriers to the development of ... AstraZeneca: Get In Before The Bounce Back
AstraZeneca (AZN) continued its long decline last month with another round of bad news. Since it paid out a $1.95 dividend to shareholders last quarter, its stock price has dropped over $6. Going forward, I expect its price to continue to slide, as it will ... AstraZeneca (AZN) Showing Bullish Technicals With Support At $42.54
Thursday, June 14, 2012... AstraZeneca (NYSE:AZN) closed Wednesday's downbeat trading session at $41.76. In the past year, the stock has hit a 52-week low of $39.72 and 52-week..... Friday, June 08, 2012... AstraZeneca Plc (NYSE: AZN) closed Thursday's ...